Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Formulation of RNA interference-based drugs for pulmonary delivery : challenges and opportunities. / Thanki, Kaushik; Blum, Kevin G; Thakur, Aneesh; Rose, Fabrice; Foged, Camilla.

In: Therapeutic Delivery, Vol. 9, No. 10, 10.2018, p. 731-749.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Thanki, K, Blum, KG, Thakur, A, Rose, F & Foged, C 2018, 'Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities', Therapeutic Delivery, vol. 9, no. 10, pp. 731-749. https://doi.org/10.4155/tde-2018-0029

APA

Thanki, K., Blum, K. G., Thakur, A., Rose, F., & Foged, C. (2018). Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Therapeutic Delivery, 9(10), 731-749. https://doi.org/10.4155/tde-2018-0029

Vancouver

Thanki K, Blum KG, Thakur A, Rose F, Foged C. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Therapeutic Delivery. 2018 Oct;9(10):731-749. https://doi.org/10.4155/tde-2018-0029

Author

Thanki, Kaushik ; Blum, Kevin G ; Thakur, Aneesh ; Rose, Fabrice ; Foged, Camilla. / Formulation of RNA interference-based drugs for pulmonary delivery : challenges and opportunities. In: Therapeutic Delivery. 2018 ; Vol. 9, No. 10. pp. 731-749.

Bibtex

@article{e45dd1807cd14863a00450b8dd765eed,
title = "Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities",
abstract = "With recent advances in the field of RNAi-based therapeutics, it is possible to make any target gene 'druggable', at least in principle. The present review focuses on aspects critical for pulmonary delivery of formulations of nucleic acid-based drugs. The first part introduces the therapeutic potential of RNAi-based drugs for the treatment of lung diseases. Subsequently, we discuss opportunities for formulation-enabled pulmonary delivery of RNAi drugs in light of key physicochemical properties and physiological barriers. In the following section, an overview is included of methodologies for imparting inhalable characteristics to nucleic acid formulations. Finally, we review one of the bottlenecks in the early preclinical testing of inhalable nucleic acid-based formulations, in other words, devices suitable for pulmonary administration of powder-based formulations in rodents.",
author = "Kaushik Thanki and Blum, {Kevin G} and Aneesh Thakur and Fabrice Rose and Camilla Foged",
year = "2018",
month = oct,
doi = "10.4155/tde-2018-0029",
language = "English",
volume = "9",
pages = "731--749",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "10",

}

RIS

TY - JOUR

T1 - Formulation of RNA interference-based drugs for pulmonary delivery

T2 - challenges and opportunities

AU - Thanki, Kaushik

AU - Blum, Kevin G

AU - Thakur, Aneesh

AU - Rose, Fabrice

AU - Foged, Camilla

PY - 2018/10

Y1 - 2018/10

N2 - With recent advances in the field of RNAi-based therapeutics, it is possible to make any target gene 'druggable', at least in principle. The present review focuses on aspects critical for pulmonary delivery of formulations of nucleic acid-based drugs. The first part introduces the therapeutic potential of RNAi-based drugs for the treatment of lung diseases. Subsequently, we discuss opportunities for formulation-enabled pulmonary delivery of RNAi drugs in light of key physicochemical properties and physiological barriers. In the following section, an overview is included of methodologies for imparting inhalable characteristics to nucleic acid formulations. Finally, we review one of the bottlenecks in the early preclinical testing of inhalable nucleic acid-based formulations, in other words, devices suitable for pulmonary administration of powder-based formulations in rodents.

AB - With recent advances in the field of RNAi-based therapeutics, it is possible to make any target gene 'druggable', at least in principle. The present review focuses on aspects critical for pulmonary delivery of formulations of nucleic acid-based drugs. The first part introduces the therapeutic potential of RNAi-based drugs for the treatment of lung diseases. Subsequently, we discuss opportunities for formulation-enabled pulmonary delivery of RNAi drugs in light of key physicochemical properties and physiological barriers. In the following section, an overview is included of methodologies for imparting inhalable characteristics to nucleic acid formulations. Finally, we review one of the bottlenecks in the early preclinical testing of inhalable nucleic acid-based formulations, in other words, devices suitable for pulmonary administration of powder-based formulations in rodents.

U2 - 10.4155/tde-2018-0029

DO - 10.4155/tde-2018-0029

M3 - Journal article

C2 - 30277138

VL - 9

SP - 731

EP - 749

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 10

ER -

ID: 203516078